# SRN-101

Source: https://onco.cc/drugs/srn-101/  
OnCo record `srn-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SRN-101 is an experimental AAV gene therapy from Siren Biotechnology, in phase 1 trials for recurrent high-grade glioma.

## Summary

SRN-101 is an AAV gene therapy (immuno-gene therapy) from Siren Biotechnology. An adeno-associated virus vector that carries the gene for human interferon beta, infused once directly into the tumour by MRI-guided convection-enhanced delivery so that the tumour makes the immune signal itself. Its furthest stage is phase 1, for recurrent high-grade glioma. ClinicalTrials.gov registers it in 2 studies linked below. Both registered trials are not yet recruiting (company-sponsored phase 1/2 ALERT-1 NCT07902037; investigator-initiated phase 1 NCT07826949 sponsored by Nicholas Butowski). FDA granted Orphan Drug, Rare Pediatric Disease and Fast Track designations. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: SRN-101
- Modality: AAV gene therapy (immuno-gene therapy)
- Mechanism: An adeno-associated virus vector that carries the gene for human interferon beta, infused once directly into the tumour by MRI-guided convection-enhanced delivery so that the tumour makes the immune signal itself.

## Sources

- Siren Biotechnology: sirenbiotechnology.com: https://sirenbiotechnology.com/pipeline-assets/
- Siren Biotechnology: sirenbiotechnology.com: https://sirenbiotechnology.com/pipeline-assets/
- Siren Biotechnology: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07902037
- ClinicalTrials.gov: trials of SRN-101: https://clinicaltrials.gov/search?intr=SRN-101

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- companies: [Siren Biotechnology](https://onco.cc/companies/siren-biotechnology/)
- trials: [A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.](https://onco.cc/trials/nct07826949/), [A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)](https://onco.cc/trials/nct07902037/)

---
JSON: https://onco.cc/api/v1/entities/srn-101.json